AusBiotech

Arovella Therapeutics (ASX:ALA) has reinforced its commitment to sustainable business practices with the release of its fourth Environmental, Social, and Governance Report, outlining progress in governance, environmental responsibility, social impact, and long-term value creation.

Actinogen Medical (ASX:ACW) has launched a new Investor Hub, designed to strengthen engagement with shareholders as the company moves closer to pivotal milestones in its late-stage Alzheimer’s disease trial.

Lumos Diagnostics (ASX:LDX) has broadened access to its flagship rapid diagnostic test, FebriDx, through a new distribution agreement with Amtech Medical, part of the Australasian healthcare alliance YesGroup.

Australian biotechnology company Cartherics has been recognised as a regional leader in cell and gene therapy, winning the award for ‘Most Promising iPSC Therapy Pipeline in APAC’ at the Asia Pacific Cell and Gene Therapy Excellence Awards 2025 in Singapore.

Australian biotech HaemaLogiX has been recognised as a rising leader in advanced cancer therapies, taking home the award for 'Most Promising CAR-T Pipeline in APAC' at the Asia Pacific CGT Excellence Awards 2025, held in Singapore.

A University of Queensland PhD student is pioneering the use of sponge-like gold particles to make ovarian cancer diagnosis more accurate, less invasive, and potentially accessible for women in remote communities.

Alterity Therapeutics (ASX:ATH) has secured $20 million in new funding to accelerate the development of its lead drug candidate ATH434, a potential disease-modifying therapy for multiple system atrophy (MSA), a rare and devastating neurodegenerative disorder.

Regenerative medicine company Orthocell (ASX:OCC) has reported promising interim results from its ongoing Remplir Real-World Evidence study, reinforcing the performance of its collagen nerve wrap in routine clinical practice and laying the groundwork for international expansion.

Proteomics International Laboratories (ASX:PIQ) has unveiled new clinical results that could transform the early detection landscape for esophageal adenocarcinoma, a deadly cancer that has long eluded timely diagnosis.

AVITA Medical (ASX:AVH) has reinforced the economic case for its RECELL System after new real-world data showed the technology can cut hospital stays for burn patients by more than a third, potentially unlocking significant savings for US healthcare providers.

Botanix Pharmaceuticals (ASX:BOT) has welcomed news that its partner Dongwha Pharm has secured regulatory approval for ECCLOCK gel, 5% (sofpironium bromide) in South Korea, paving the way for the product’s commercial launch in the first quarter of 2026.

A world-leading Australian virologist has been recognised for transforming the way infectious diseases are detected and understood.